HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.

Abstract
Esophageal adenocarcinoma (EAC) arises in the backdrop of reflux-induced metaplastic phenomenon known as Barrett esophagus. The prognosis of advanced EAC is dismal, and there is an urgent need for identifying molecular targets for therapy. Serial Analysis of Gene Expression (SAGE) was performed on metachronous mucosal biopsies from a patient who underwent progression to EAC during endoscopic surveillance. SAGE confirmed significant upregulation of Axl "tags" during the multistep progression of Barrett esophagus to EAC. In a cohort of 92 surgically resected EACs, Axl overexpression was associated with shortened median survival on both univariate (p < 0.004) and multivariate (p < 0.036) analysis. Genetic knockdown of Axl receptor tyrosine kinase (RTK) function was enabled in two EAC lines (OE33 and JH-EsoAd1) using lentiviral short hairpin RNA (shRNA). Genetic knockdown of Axl in EAC cell lines inhibited invasion, migration, and in vivo engraftment, which was accompanied by downregulation in the activity of the Ral GTPase proteins (RalA and RalB). Restoration of Ral activation rescued the transformed phenotype of EAC cell lines, suggesting a novel effector mechanism for Axl in cancer cells. Pharmacological inhibition of Axl was enabled using a small molecule antagonist, R428 (Rigel Pharmaceuticals). Pharmacological inhibition of Axl with R428 in EAC cell lines significantly reduced anchorage-independent growth, invasion and migration. Blockade of Axl function abrogated phosphorylation of ERBB2 (Her-2/neu) at the Tyr877 residue, indicative of receptor crosstalk. Axl RTK is an adverse prognostic factor in EAC. The availability of small molecule inhibitors of Axl function provides a tractable strategy for molecular therapy of established EAC.
AuthorsAlvarez Hector, Elizabeth A Montgomery, Collins Karikari, Marcia Canto, Kerry B Dunbar, Jean S Wang, Georg Feldmann, Seung-Mo Hong, Michael C Haffner, Alan K Meeker, Sacha J Holland, Jiaxin Yu, Thilo J Heckrodt, Jing Zhang, Pingyu Ding, Dane Goff, Rajinder Singh, Juan Carlos Roa, Arivusudar Marimuthu, Gregory J Riggins, James R Eshleman, Barry D Nelkin, Akhilesh Pandey, Anirban Maitra
JournalCancer biology & therapy (Cancer Biol Ther) Vol. 10 Issue 10 Pg. 1009-18 (Nov 15 2010) ISSN: 1555-8576 [Electronic] United States
PMID20818175 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Benzocycloheptenes
  • Intercellular Signaling Peptides and Proteins
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Quinazolines
  • RNA, Small Interfering
  • Triazoles
  • growth arrest-specific protein 6
  • bemcentinib
  • Lapatinib
  • Receptor Protein-Tyrosine Kinases
  • ral GTP-Binding Proteins
  • Axl Receptor Tyrosine Kinase
Topics
  • Adenocarcinoma (drug therapy, enzymology, pathology)
  • Aged
  • Animals
  • Barrett Esophagus (drug therapy, enzymology, pathology)
  • Benzocycloheptenes (pharmacology)
  • Cell Movement (drug effects)
  • Esophageal Neoplasms (drug therapy, enzymology, pathology)
  • Female
  • Humans
  • Immunoenzyme Techniques
  • Intercellular Signaling Peptides and Proteins (genetics, metabolism)
  • Lapatinib
  • Lymphatic Metastasis
  • Male
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Middle Aged
  • Phosphorylation (drug effects)
  • Protein Kinase Inhibitors (pharmacology)
  • Proto-Oncogene Proteins (antagonists & inhibitors, genetics, metabolism)
  • Quinazolines (pharmacology)
  • RNA, Small Interfering (genetics)
  • Receptor Protein-Tyrosine Kinases (antagonists & inhibitors, genetics, metabolism)
  • Signal Transduction (drug effects)
  • Survival Rate
  • Triazoles (pharmacology)
  • ral GTP-Binding Proteins (antagonists & inhibitors, genetics, metabolism)
  • Axl Receptor Tyrosine Kinase

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: